SUBSCRIBE
SUBSCRIBE
News   Business

ImmunoGen, Inc. Licenses Anti-Cancer Technology to Amgen (JOBS); ImmunoGen to Get Up to $34 Million in Milestone Payments

November 20, 2009 | 
1 min read

Bookmark and Share

Reuters -- Drugmaker ImmunoGen Inc said it licensed its technology to develop anti-cancer drugs to Amgen Inc for a $1 million upfront payment.

Alliances
Amgen
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Cellectar Downsizes by 60% as it Explores Strategic Options for Cancer Drug
December 11, 2024
 · 
202 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie